Characterization of an intraperitoneal ovarian cancer xenograft model in nude rats using noninvasive microPET imaging

International Journal of Gynecological Cancer

Volumn 17, Issue 2, 2007, Pages 407-417

  Zavaleta, C L ^a   Phillips, W T ^a   Bradley, Y C ^b   McManus, L M ^c   Jerabek, P A ^a   Goins, B A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

Author keywords

18F FDG; Intraperitoneal delivery; MicroPET; Nude rats; Ovarian cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; AUTOPSY; CANCER CELL; CANCER MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIET RESTRICTION; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; INOCULATION; LAPAROSCOPY; LYMPH NODE; NON INVASIVE PROCEDURE; NONHUMAN; NUDE RAT; OVARY CANCER; PERITONEAL CAVITY; PERITONEAL FLUID; PERITONEUM CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SOLID TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT;

ALGORITHMS; ANIMALS; CARCINOMA; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; OVARIAN NEOPLASMS; PERITONEAL CAVITY; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, NUDE; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33947311832     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00814.x     Document Type: Article

References (49)

1. The National Ovarian Cancer Coalition Web site [online]. Available at: http://www.ovarian.org/default.asp. Accessed April 11, 2005.
2. American Cancer Society Website [online]. Available at: http://www.cancer.org/docroot/CRI/CRI_2_3x.asp?dt=33. Accessed August 31, 2006.
3. California Cancer Registry Web site [online]. Available at: http://www.ccrcal.org/. Accessed March 31, 2005.
4. National Cancer Institute Web site [online]. Available at: http://nci.nih.gov/cancertopics/pdq/treatment/ovarianepithelial/Patient/page1. Accessed March 31, 2005.
5. de Bree E, Witkamp AJ, Zoetmulder FA. Intraperitoneal chemotherapy for colorectal cancer. J Surg Oncol 2002;79:46-61.
6. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001;61:1057-65.
7. Schneider JG. Intraperitoneal chemotherapy. Obstet Gynecol Clin North Am 1994;21:195-212.
8. Piver MS, Lele SB, Bakshi S, Parthasarathy KL, Emrich LJ. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma. Am J Clin Oncol 1988;11:515-9.
9. Lecuru F, Guilbaud N, Agostini A, Augereau C, Vilde F, Taurelle R. Description of two new human ovarian carcinoma models in nude rats suitable for laparoscopic experimentation. Surg Endosc 2001;15:1346-52.
10. Lewis JS, Connett JM, Garbow JR et al. Copper-64- pyruvaldehydebis(N(4)-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging. Cancer Res 2002;62:445-9.
11. Hamilton TC, Young RC, Louie KG et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 1984;44:5286-90.
12. Kumar R, Alavi A. PET imaging in gynecologic malignancies. Radiol Clin North Am 2004;42:1155-67, ix.
13. Tammela J, Lele S. New modalities in detection of recurrent ovarian cancer. Curr Opin Obstet Gynecol 2004;16:5-9.
14. Togashi K. Ovarian cancer: the clinical role of US, CT, and MRI. Eur Radiol 2003;13(Suppl. 4):L87-104.
15. Yen TC, Lai CH. Positron emission tomography in gynecologic cancer. Semin Nucl Med 2006;36:93-104.
16. Pandit-Taskar N. Oncologic imaging in gynecologic malignancies. J Nucl Med 2005;46:1842-50.
17. Nakamoto Y, Saga T, Fujii S. Positron emission tomography application for gynecologic tumors. Int J Gynecol Cancer 2005;15:701-9.
18. Picchio M, Sironi S, Messa C et al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med 2003;47:77-84.
19. Baum RP, Przetak C. Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET). Q J Nucl Med 2001;45:257-68.
20. Zimny M, Siggelkow W. Positron emission tomography scanning in gynecologic and breast cancers. Curr Opin Obstet Gynecol 2003;15:69-75.
21. Kumar R, Bhargava P, Bozkurt MF, Zhuang H, Potenta S, Alavi A. Positron emission tomography imaging in evaluation of cancer patients. Indian J Cancer 2003;40:87-100.
22. McQuarrie S, Mercer J, Syme A, Suresh M, Miller G. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. J Pharm Pharm Sci 2005;7:29-34.
23. American Type Culture Collection Web site [online]. Available at: http://www.atcc.org/. Accessed February 17, 2004.
24. Gawronska B, Leuschner C, Enright FM, Hansel W. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol 2002;85:45-52.
25. Xiao Z, McQuarrie SA, Suresh MR, Mercer JR, Gupta S, Miller GG. A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. J Biotechnol 2002;94:171-84.
26. Suzuki T, Nakamura K, Kawase T, Kubo A. Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime). Ann Nucl Med 2003;17:131-8.
27. Liu Z, Stevenson GD, Barrett HH et al. 99mTc glucarate high-resolution imaging of drug sensitive and drug resistant human breast cancer xenografts in SCID mice. Nucl Med Commun 2004;25:711-20.
28. Min JJ, Chung JK, Lee YJ et al. In vitro and in vivo characteristics of a human colon cancer cell line, SNU-C5N, expressing sodium-iodide symporter. Nucl Med Biol 2002;29:537-45.
29. Hamann PR, Hinman LM, Beyer CF et al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjug Chem 2005;16:354- 60.
30. Ihle NT, Williams R, Chow S et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3:763-72.
31. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003;4:277-83.
32. Chaudhuri TR, Mountz JM, Rogers BE, Partridge EE, Zinn KR. Light-based imaging of green fluorescent protein-positive ovarian cancer xenografts during therapy. Gynecol Oncol 2001;82:581-9.
33. Kanerva A, Zinn KR, Chaudhuri TR et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003;8:449-58.
34. Lockley M, Fernandez M, Wang Y et al. Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res 2006;66:989-98.
35. Klostergaard J, Auzenne E, Ghosh S, Farquhar D, Rivera B, Price RE. Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response. Int J Gynecol Cancer 2006;16(Suppl. 1):111-7.
36. Gossmann A, Helbich TH, Mesiano S et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 2000;183:956-63.
37. Chaudhuri TR, Cao Z, Krasnykh VN et al. Blood-based screening and light based imaging for the early detection and monitoring of ovarian cancer xenografts. Technol Cancer Res Treat 2003;2:171-80.
38. Wang J, Maurer L. Positron emission tomography: applications in drug discovery and drug development. Curr Top Med Chem 2005;5:1053-75.
39. Abbey CK, Borowsky AD, McGoldrick ET et al. In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci U S A 2004;101:11438-43.
40. Palm S, Enmon RM Jr, Matei C et al. Pharmacokinetics and biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 2003;44:1148-55.
41. Martensson L, Wang Z, Nilsson R et al. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy. Clin Cancer Res 2005;11(Suppl. 19, pt 2):7104s-8s.
42. Zhuang H, Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59.
43. Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005;43:121-34.
44. El-Haddad G, Zhuang H, Gupta N, Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 2004;34:313-29.
45. Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1182-206.
46. Green MV, Seidel J, Vaquero JJ, Jagoda E, Lee I, Eckelman WC. High resolution PET, SPECT and projection imaging in small animals. Comput Med Imaging Graph 2001;25:79-86.
47. Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small animal imaging. Current technology and perspectives for oncological imaging. Eur J Cancer 2002;38:2173-88.
48. Phelps ME. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 2000;97:9226-33.
49. Gamma Medica Web site [online]. Available at: http://www.gammamedica.com. Accessed August 24, 2005.